Benzinga · Sep 9, 2026
This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiate coverage: Buy ratings for Robinhood ($170), TriSalus ($11), Kodiak AI ($8); Underperform for Deckers ($70).
TL
NASDAQ · TLSI
TriSalus Life Sciences, Inc.
Healthcare · Medical - Devices
$4.93
Up+$0.09 (+1.83%)
Updated Sep 17, 2026, 2:09 PM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 247.45M
- P/E ratio
- -4.6
- Dividend yield
- 0.00%
- 52-week range
- $2.20 – $7.95
- Volume
- 156.51K
- Avg. volume
- 137.4K
Price performance
TLSI price history
1M range · 0 trading sessions · Daily adjusted prices
TLSI does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest TLSI news
The latest Smart Investors Daily articles mentioning TLSI.
Stock researchCompany · Overview
TLSI research
Overview
Company profile and research snapshot.
Company profile
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $10.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | HC Wainwright & Co. | Buy | — |
| May 13, 2026 | Lake Street | Buy | — |
| Mar 9, 2026 | Canaccord Genuity | Buy | — |
| Mar 6, 2026 | Canaccord Genuity | Buy | — |
| Dec 17, 2025 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 9, 2026
HC Wainwright & Co. Initiates Coverage On TriSalus Life Sciences with Buy Rating, Announces Price Target of $11
HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a Buy rating and announces Price Target of $11.
Yahoo · Aug 31, 2026
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
WESTMINSTER, Colo., August 31, 2026--TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
SeekingAlpha · Aug 7, 2026
Wasatch Micro Cap Fund Q2 2026 Contributors And Detractors
Wasatch Micro Cap Fund's Q2 2026 report analyzes semiconductor gains and consumer sector challenges. Read the full analysis for more details.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
